Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02057770 PHASE1 TERMINATED

The purpose of this research study is to look at overall health status and how acute myeloid leukemia (AML) responds to a stem cell transplant when followed with cyclophosphamide. Some participants enrolling in this study may receive a transplant from a sibling, some may receive a transplant from a matched unrelated donor, and some may receive what is called a haploidentical transplant. A haploidentical stem cell transplant is a type of transplant that occurs when a person who needs a transplant cannot find a donor who exactly matches their tissue type (either among family members or through a matched unrelated donor). When no matched donor is available, half-matched related (haploidentical) donors may be used. Haploidentical donors are first degree relatives such as siblings, children, or parents. People who undergo a stem cell transplant can experience complications such as rejection of the stem cell transplant or severe graft-versus-host disease (GVHD). GVHD occurs when some of the cells from the donor attack the recipient's tissues, resulting in mild, moderate, or even life-threatening side effects to the recipient's skin, stomach, intestines, and liver. However, recent research has shown that receiving cyclophosphamide after stem cell transplant can improve the outcomes of the transplant, and that is the purpose of this study.

Details

Lead sponsor	Washington University School of Medicine
Phase	PHASE1
Status	TERMINATED
Enrolment	25
Start date	Fri Feb 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Leukemia, Myeloid, Acute

Interventions

• busulfan
• fludarabine phosphate
• total-body irradiation (TBI)
• Stem cell transplant
• cyclophosphamide
• tocilizumab

Countries

United States